Drug intelligence / Profile preview

YK0901

Development stage: Phase 1
Lead developer: Yingkai Saiwei
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

YK0901 is a KRAS G12V-specific T cell receptor (TCR) modified T cell therapy. It functions as a KRAS G12V inhibitor through immunologic cytotoxicity and T lymphocyte replacement mechanisms. This therapy is designed for patients with advanced solid tumors who are HLA-A*11:01 positive and have KRAS G12V mutations, which are common in pancreatic, lung, and colorectal cancers.

Targets

KRASG12V (KRAS G12V)KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)

Beyond the preview

Go deeper on YK0901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YK0901.

Explore the full profile